Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the United ...

Axsome Therapeutics has reached a settlement agreement with Hetero Labs to resolve a patent dispute related to Hetero Labs’s plans to release a generic of Sunosi, which is a sleep disorder therapy.

Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders. The company has a diverse pipeline ...

Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include ...

Axsome Therapeutics filed a patent infringement lawsuit on Aug. 21 in New Jersey federal court. The suit, brought by Saul Ewing and Quinn Emanuel Urquhart & Sullivan, takes aim at Aurobindo Pharma ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...

Axsome Therapeutics, Inc. AXSM announced that it has dosed the first patient in the phase III PARADIGM study evaluating its investigational therapy, solriamfetol, for treating major depressive ...